Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06570473 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Feasibility Trial for a Right Ventricular Failure Platform Trial

Study acronym: CRAVE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 7 months later Aug 2026 → Mar 31, 2027
See other at-risk trials from University of Alberta

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Aug 2026 to Mar 31, 2027
    • Study completion pushed from Dec 2026 to Jun 2027
    • Eligibility criteria expanded, about 28 words
    • Secondary endpoints: details revised at 4 of 10 entries
  2. Primary completion date: Aug 2025 to Aug 2026
    • Start date: Feb 12, 2025 to Jul 15, 2025
    • Study completion date: Dec 2025 to Dec 2026
    v6
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 5
    • Start date changed from estimate of Feb 2025 to Feb 12, 2025
    v5
  4. Start date: Dec 2024 to Feb 2025v4
  5. Start date: Oct 2024 to Dec 2024v3
  6. Start date: Sep 2024 to Oct 2024v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Alberta
248 trials monitored
See 16 trials at risk
Heart Disease
8,786 trials monitored
See 412 trials at risk
Heart Failure
1,995 trials monitored
See 111 trials at risk
Hypertension
1,925 trials monitored
See 99 trials at risk
The primary objective of the CRAVE feasibility trial is to assess the feasibility of conducting a larger CRAVE platform trial by performing a randomized trial of 30 participants with pulmonary hypertension and right ventricular dysfunction, comparing empagliflozin or ranolazine plus standard of care to standard of care alone.
Trial Details
NCT Number NCT06570473
Lead Sponsor University of Alberta
Collaborators: Canadian Heart Function Alliance, Accelerating Clinical Trials Consortium, Ottawa Heart Institute Research Corporation, Team PHenomenal Hope
Conditions
(from sponsor)		 Pulmonary Hypertension, Right Ventricular Dysfunction, Right Heart Failure
Related terms Heart Failure, Hypertension, Pulmonary, Ventricular Dysfunction, Right
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov